Patent · US Active

Puumala virus full-length M segment-based DNA vaccines

US8852598B2 · kind B2 · utility

2Cited by
1References
7Claims
0Family size

Assignee

Inventor

Key dates

Filing dateApr 11, 2012
Grant dateOct 7, 2014
Priority date
Expiry dateJul 8, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/12134
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.